P/E ratio for Aeterna Zentaris (AEZS)

P/E ratio history for Aeterna Zentaris from 2018 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Spectrum Pharmaceuticals SPPI	-2.86	133.09%	🇺🇸 USA
Novartis NVS	31.1	-2,633.32%	🇨🇭 Switzerland
Bristol-Myers Squibb BMY	12.4	-1,111.33%	🇺🇸 USA
Sanofi SNY	18.1	-1,576.82%	🇫🇷 France
Halozyme Therapeutics HALO	34.1	-2,875.07%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.